undamentalytics Newsletter
Sign in

Bone Biologics Corp income statement

In fiscal 2020, Bone Biologics Corp reported revenue of $1.07bn, up 0.0% on the year before, operating income of −$825,014 (a -0.1% margin) and net income of −$1.8m, or −$54.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162019Dec 20192020Dec 2020LTMJun 2021
Revenue1,0701,0701,0701,070
Research and development10100
General and administrative6101
Operating income−20−2−1−1
Income before tax−26−3−2−2
Income tax000—
Net income−26−3−2−2
Diluted EPS−$297.47−$40.53−$54.32—
Diluted shares (average)——34m—
EBITDA−20−2——

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bone Biologics Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bone Biologics Corp.